Table 2 Grade 3–4 late adverse events.

From: Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial

 

Group A

Group B

Group C

Group D

p

N = 88

N = 88

N = 88

N = 88

Esophageal stenosis

9

10

11

7

0.800

Cardiac disorders

2

1

1

1

0.896

  1. Group A chemotherapy/extended nodal irradiation + erlotinib, Group B chemotherapy/extended nodal irradiation, Group C chemotherapy/conventional field irradiation + erlotinib, Group D chemotherapy/conventional field irradiation.
Back to article page